Immunome Historical Income Statement
| IMNM Stock | USD 9.82 0.40 4.25% |
Historical analysis of Immunome income statement accounts such as Depreciation And Amortization of 736.1 K or Interest Expense of 4.3 K can show how well Immunome performed in making a profits. Evaluating Immunome income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immunome's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Immunome latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunome is a good buy for the upcoming year.
Immunome |
About Immunome Income Statement Analysis
Immunome Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immunome shareholders. The income statement also shows Immunome investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Immunome Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immunome. It is also known as Immunome overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Immunome financial statement analysis. It represents the amount of money remaining after all of Immunome operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Immunome's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immunome current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.At this time, Immunome's Total Operating Expenses is very stable compared to the past year. As of the 24th of November 2024, Reconciled Depreciation is likely to grow to about 734.2 K, though Operating Income is likely to grow to (104.1 M).
| 2020 | 2023 | 2024 (projected) | Depreciation And Amortization | 755K | 728K | 736.1K | Interest Income | 1K | 2.7M | 2.9M |
Immunome income statement Correlations
Click cells to compare fundamentals
Immunome Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunome income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (96K) | (38K) | (10K) | 5K | 2.7M | 2.9M | |
| Interest Expense | 106K | 38K | 10K | 5K | 4.5K | 4.3K | |
| Selling General Administrative | 1.5M | 4.8M | 11.1M | 13.6M | 19.7M | 20.6M | |
| Other Operating Expenses | 10.3M | 12.3M | 25.2M | 36.9M | 123.5M | 129.7M | |
| Operating Income | (10.3M) | (12.3M) | (25.2M) | (36.9M) | (109.5M) | (104.1M) | |
| Net Income From Continuing Ops | (10.4M) | (17.8M) | (24.7M) | (36.9M) | (106.8M) | (101.5M) | |
| Ebit | (10.3M) | (12.3M) | (24.7M) | (36.9M) | (29.0M) | (30.4M) | |
| Research Development | 8.8M | 7.5M | 14.1M | 23.3M | 80.8M | 84.8M | |
| Ebitda | (9.7M) | (11.5M) | (23.9M) | (36.3M) | (28.3M) | (29.7M) | |
| Total Operating Expenses | 10.3M | 12.3M | 25.2M | 36.9M | 122.8M | 129.0M | |
| Income Before Tax | (10.4M) | (17.8M) | (24.7M) | (36.9M) | (106.8M) | (101.5M) | |
| Total Other Income Expense Net | (96K) | (5.6M) | 493K | 5K | 2.7M | 2.9M | |
| Net Income Applicable To Common Shares | (10.4M) | (17.8M) | (24.7M) | (37.5M) | (33.8M) | (32.1M) | |
| Net Income | (10.6M) | (17.1M) | (24.5M) | (37.5M) | (106.8M) | (101.5M) | |
| Income Tax Expense | 106K | (717K) | (242K) | 617K | 560.1K | 588.1K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.